**Abstract**

The β-amyloid precursor protein (APP) has been extensively studied for its role as the precursor of the β-amyloid protein (Aβ) of Alzheimer’s disease. However, the normal function of APP remains largely unknown. This article reviews studies on the structure, expression and post-translational processing of APP, as well as studies on the effects of APP in vitro and in vivo. We conclude that the published data provide strong evidence that APP has a trophic function. APP is likely to be involved in neural stem cell development, neuronal survival, neurite outgrowth and neurorepair. However, the mechanisms by which APP exerts its actions remain to be elucidated. The available evidence suggests that APP interacts both intracellularly and extracellularly to regulate various signal transduction mechanisms.

**Keywords:** Alzheimer’s disease, amyloid precursor protein, growth factor, heparin, neurotrophic, receptor.

J. Neurochem. (2014) 129, 756–769.

The β-amyloid precursor protein (APP) is a type I transmembrane glycoprotein that is expressed in a wide variety of mammalian and non-mammalian cells (Muller-Hill and Beyreuther 1989). APP is the precursor of the β-amyloid protein (Aβ), which is the major protein component of amyloid plaques in the Alzheimer’s disease (AD) brain (Masters et al. 1985). Aβ was identified by Glenner and Wong (1984) and the first complete cDNA sequence encoding human APP was cloned in 1987 (Kang et al. 1987). The regulation of APP expression, the mechanisms of APP trafficking, post-translational modification and proteolytic cleavage of APP are now well understood. The production of Aβ from APP, which is generally considered to be a key event in the pathogenesis of AD, has also been well studied. However, despite more than two and a half decades of APP research, the normal function of the protein remains unclear. Circumstantial evidence points towards a number of potential biological roles for APP, but a clearly defined mechanism of action has been elusive. The aim of this article is to examine the putative functions of APP in relation to the expression, post-translational processing and structure of APP.

**Expression of APP**

APP belongs to a family of evolutionarily and structurally related proteins. The human APP cDNA sequence was first cloned from a brain tissue library (Kang et al. 1987). Subsequently, a number of homologous APP family members were identified in a variety of mammalian and non-mammalian organisms (Muller and Zheng 2012). The APP family in mammals consists of three members: APP, the APP-like protein-1 (APLP1) and the APP-like protein-2 (APLP2) (Wasco et al. 1992, 1993). In humans, the APP gene is located on chromosome 21 (21q21.3), contains 18 exons and extends over a distance of approximately 240 kilobases (Yoshikai et al. 1990) (Fig. 1).

Received January 5, 2014; revised manuscript received February 2, 2014; accepted February 3, 2014.

Address correspondence and reprint requests to Prof David H. Small, Menzies Research Institute Tasmania, Medical Sciences Precinct, University of Tasmania, 17 Liverpool St., Hobart, Tasmania 7001, Australia. E-mail: d.h.small@menzies.utas.edu.au

**Abbreviations used:** Aβ, β-amyloid; AD, Alzheimer’s disease; ADAM, A disintegrin and metalloprotease; AICD, APP intracellular domain; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APLP, APP-like protein; APP, β-amyloid precursor protein; BACE, β-site APP-cleaving enzyme 1; CuBD, copper/metal-binding domain; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; HBD, heparin-binding domain; KO, knock-out; KPI, Kunitz protease inhibitor; LRP, low-density lipoprotein-receptor related family proteins; LTP, long-term potentiation; NGF, nerve growth factor; NSPCs, neural stem or progenitor cells; RIP, regulated intramembrane proteolysis; sAPP, secreted β-amyloid precursor protein; Tip60, Tat-interactive protein 60; TrkA, tyrosine receptor kinase A.
Fig. 1 Structure of the amyloid precursor protein (APP) gene, mRNA and protein. (a) The APP gene is located on chromosome 21q21.3. The gene has 18 exons. Differential mRNA splicing of Exons 7,8 (dark grey) can lead to the expression of 695, 751 and 770 amino-acid isoforms. Exons 2 and 15 (light grey) are spliced out in APP639 and L-APP, respectively. (b) Protein structure. APP has an N-terminal signal peptide (SP). The E1 domain has a heparin-binding domain (HBD1), and a copper-binding domain (CuBD); the E2 domain contains a second heparin-binding domain (HBD2). APP751 and APP770 contain a Kunitz protease inhibitor (KPI) and an Ox-2 antigen domain. Between the E2 and Aβ region is shown along with the secretase cleavage sites. The intracellular C-terminal domain contains a YENPTY sorting motif. TMD, transmembrane domain.

The APP promoter sequence indicates that the APP gene belongs to the class of housekeeping genes. The promoter lacks typical TATA and CAAT boxes, but contains consenus sequences for the binding of a number of transcription factors including SP-1, AP-1 and AP-4 sites, a heat shock control element and two Alu-type repetitive sequences (Salbaum et al. 1988; Izumi et al. 1992; Quitschke and Goldgaber 1992). The presence of SP-1, AP-1 and AP-4 sites in the APP promoter, which regulate the expression of proteins associated with cell proliferation and mitosis, as well as cell differentiation, suggests that APP has a function related to cell growth or maturation. Consistent with this idea, the expression of APP or APP-like proteins is increased during development and in association with neurite outgrowth and synaptogenesis (Clarris et al. 1995).

During transcription, differential splicing of APP mRNA can result in a number of APP splice variants (Fig. 1). The major expressed isoforms of APP have 700, 751 or 695 amino acid residues. The APP751 and APP695 isoforms are produced as a result of splicing out of exons 7 and/or 8 (Fig. 1a) (Kang et al. 1987; Tanzi et al. 1988; Weidemann et al. 1989). Some less common splice variants have also been reported, such as L-APP, which lacks exon 15 (Pangalos et al. 1996) and APP639, which lacks exons 2, 7 and 8 (Tang et al. 2003).

APP mRNA is expressed in a wide variety of tissues including the nervous system (brain, spinal cord, retina), immune system (thymus, spleen), muscle (smooth, cardiac and skeletal), kidney, lung, pancreas, prostate gland and thyroid gland (Liu et al. 2008). However, the mRNA splice variants of APP are expressed in different amounts in different cells. APP695 is the predominant neuronal isoform (Kang et al. 1987), but non-neuronal cells express mostly APP770 and APP751 (Rohan de Silva et al. 1997). L-APP is expressed in leucocytes, microglia and astrocytes (Konig et al. 1992). APP639 is expressed widely in foetal tissue, but only in the liver of adults (Tang et al. 2003). The widespread expression, distribution and sequence homology of the APP gene family members suggest that APP plays an important role that is common to many different tissues and organisms.

Gene knock-out (KO) studies can be a powerful method for investigating protein function. APP-KO mice are viable and fertile, indicating that the APP gene alone does not play an essential role in development (Zheng et al. 1995). Similarly, KO of the Drosophila APP homologue (APPL) does not result in a lethal phenotype (Luo et al. 1992). However, APP-KO does result in a number of subtle phenotypic abnormalities. APP-KO mice are slightly smaller, with a reduced weight of 15–20% and reduced brain weight (Zheng et al. 1995; Magara et al. 1999) and APPL-KO in

© 2014 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of The International Society for Neurochemistry, J. Neurochem. (2014) 129, 756–769
Drosophila results in a behavioural defect (Luo et al. 1992). Importantly, several studies suggest that APP may have a function that is related to the function of other APP family members. Like APP-KO mice, APLP1-KO mice and APLP2-KO mice are both viable and fertile (Heber et al. 2000). Double KO of APLP1 and APP does not produce a lethal phenotype; however, both APP/APLP2 double KO mice and APLP1/APLP2 double KO mice have a postnatal lethal phenotype (Heber et al. 2000). Furthermore, knockout of APL-1, which is the only APP gene in lethal phenotype (Hornsten et al. 2001). Therefore these studies suggest that APP has a function that is likely to be related or overlapping with that of APLP2 in mammals.

Post-translational modification, trafficking and processing of APP

After it has been expressed, the newly translated APP polypeptide can undergo a number of post-translational modifications including glycosylation, sulphation, phosphorylation and palmitoylation (Selkoe 2001; Bhattacharyya et al. 2013). After modification in the Golgi apparatus, APP is trafficked to the cell surface (Koo et al. 1996) before being internalised by clathrin-mediated endocytosis and incorporated into the endosomal-lysosomal system (Yamazaki et al. 1996). Most APP is trafficked from the endosome to the lysosome, where it is degraded (Haass et al. 1992). However, a portion can be returned to the cell surface (Yamazaki et al. 1996).

APP can be post-translationally processed by enzymes termed secretases, which can cleave the protein to produce a number of smaller fragments. The proteolytic processing of APP will not be discussed in detail, as this topic has been well reviewed elsewhere (Haass et al. 2012). APP can initially be cleaved by two proteases, α-secretase or β-secretase (Fig. 1b), to produce the secreted ectodomains sAPPα and sAPPβ. Following APP cleavage by α- or β-secretase, the membrane-associated C-terminal fragments (C83 and C99, respectively) can be cleaved by γ-secretase to yield p3 or Aβ, respectively, and a short C-terminal peptide known as the APP intracellular domain (AICD).

A number of enzymes can act as α-secretases. All of them are members of the A disintegrin and metalloprotease (ADAM) family (Buxbaum et al. 1998; Koike et al. 1999; Lammich et al. 1999). The β-secretase has been identified as a type 1 transmembrane aspartyl protease termed the β-site APP-cleaving enzyme 1 (BACE1) (Hussain et al. 1999; Sinha et al. 1999; Vassar et al. 1999; Yan et al. 1999; Lin et al. 2000). BACE1 also cleaves APP at position 11 of the Aβ sequence, although the significance of this cleavage is unclear (Fig. 1b) (Liu et al. 2002). γ-Secretase is a transmembrane complex consisting minimally of four protein subunits, presenilin 1 or 2, nicastrin, anterior pharynx-defective phenotype and presenilin enhancer 2 (De Strooper et al. 1998; Yu et al. 2000; Francis et al. 2002; Kimberly et al. 2003). γ-Secretase cleavage is a type of regulated intramembrane proteolysis (RIP), as cleavage occurs in the middle of the transmembrane domain (Lichtenthaler et al. 2011). RIP of APP is thought to occur as a series of cleavages, starting from the C terminal end of the substrate and moving towards the N-terminal region of the transmembrane domain. These cleavage sites have been termed the γ-, ε- and ζ- sites (Fig. 1b) (Lichtenthaler et al. 2011).

Although the proteolytic processing of APP by β-secretase can lead to the pathological production of Aβ, β-cleavage is a normal process. Generally, the cleavage of transmembrane proteins by an ADAM or BACE (ectodomain shedding) is commonly involved in the activation of a number of functional pathways. Ectodomain shedding by ADAMs is essential for the release of many cytokines and growth factor ligands, such as epidermal growth factor (EGF) (Blobel 2005). Additionally, ADAMs are involved in ectodomain shedding of growth-factor receptors, such as human epidermal growth factor receptor 2 (Liu et al. 2006) and Notch (Bozkulak and Weinmaster 2009). Ectodomain shedding by BACE is also likely to be required for the proper function of a number of proteins (Klaver et al. 2010). For example, neuregulin is cleaved by BACE1 and ADAM17 to release an ectodomain fragment, which acts in a paracrine manner to stimulate myelination (Fleck et al. 2013). Therefore, cleavage by ADAMs or BACE can potentially facilitate cellular signalling in a variety of ways, either by release of growth factors or by ligand-dependent activation of cellular receptors.

RIP by γ-secretase is also a process involved in the normal function of many proteins. RIP can serve two general functions. First, it can remove the membrane-associated fragment that is produced by ectodomain shedding. Second, it can catalyse the production of intracellular signalling domains (Lichtenthaler et al. 2011). γ-Secretase has over 80 currently known substrates (Haapasalo and Kovacs 2011). Apart from APP, the most well known γ-secretase substrate is the developmental protein Notch, which is activated by γ-secretase cleavage (De Strooper et al. 1999; Struhl and Greenwald 1999). Therefore, it is also possible that γ-secretase cleavage may also be involved in the function of APP.

Structure of APP

Structurally, APP has features of an integral type I transmembrane glycoprotein (Fig. 1b). The structure of APP suggests that it may act as a cell-surface receptor (Kang et al. 1987) or as a growth factor (Rossjohn et al. 1999). The encoded protein contains a large ectodomain, which includes a cysteine-rich globular domain (E1), an acidic domain, a helix-rich domain (E2) and part of the Aβ sequence, which extends into the transmembrane domain (Fig. 1b). The relatively short cytoplasmic domain contains
the C-terminus, which has some phosphorylation sites and a YENPTY sorting motif (Fig. 1b). This section will discuss the structure and putative interactions of these domains.

**E1 domain and acidic region**

The cysteine-rich E1 domain of APP shares little amino-acid sequence similarity to non-APP family members. Cysteine-rich globular domains are found in a number of transmembrane domain proteins including scavenger receptors and hepsin, a cell-surface serine protease (Wu and Parry 2007). The E1 domain is divided into two distinct regions, the heparin-binding domain (HBD) and the copper/metal binding domain (Fig. 2). The HBD is formed of a single α-helix and an anti-parallel β-sheet, with a loop rich in basic residues (95-110) that binds to heparin (Small et al. 1994; Rossjohn et al. 1999). Immediately adjacent to the HBD is a hydrophobic pocket, which could form either a protein-binding site or a dimerisation site (Rossjohn et al. 1999). It has been proposed that this region may dimerise in the presence of heparin (Gralle et al. 2006; Dahms et al. 2010). The size of the putative binding domain at the N-terminus suggests that APP may act as a receptor for a ligand or act as a growth factor (Rossjohn et al. 1999), or may bind to an extracellular matrix component (e.g. proteoglycan) (Small et al. 1994).

Adjacent to the HBD is the copper/metal binding domain, which contains a single α-helix and a short β-sheet (Fig. 2). This region can bind several metal ions (Bush et al. 1993). The role of this domain is unclear, but it has been suggested that copper (II) binding and reduction may be a principal function (Multhaup et al. 1996). On the C-terminal side of the E1 domain is an acidic region of unknown significance that is rich in glutamic acid and aspartic acid residues. This region also contains a stretch of seven threonine residues (Kang et al. 1987).

**KPI and Ox-2 antigen domains**

Longer isoforms of APP (APP770 and APP751) may contain a Kunitz-type protease inhibitor (KPI) domain and an Ox-2 antigen domain. APP isoforms containing the KPI domain are more commonly expressed in non-neuronal cells (Rohan de Silva et al. 1997), suggesting that they may play a role in glial functions such as in wound repair. Clues to the function of these isoforms comes from studies on blood coagulation. KPI-containing forms of APP (APP751 and APP770) are highly expressed in platelets where they can influence wound repair by regulating blood clotting serine proteases (Van Nostrand et al. 1991b). As serine proteases are also implicated in neuronal cell growth (Wang and Reiser 2003), it is possible that KPI-containing APP isoforms regulate cell growth by inhibiting one or more of these proteases.

The role of the Ox-2 domain in APP770 is less clear. The Ox-2 antigen is a lymphoid and neuronal cell-surface glycoprotein, which has homology to Thy-1 and immunoglobulin light chains (Clark et al. 1985). In APP, the Ox-2 domain is an insert of 19 amino-acid residues that is similar to a region of the Ox-2 antigen. As immunoglobulin loop domains are commonly found in cell-surface receptors and are involved in cell-surface binding and recognition, it seems likely that the Ox-2 domain in APP has a similar function.

**E2 domain**

The E2 domain is a α-helix rich region (Fig. 2) that can readily dimerize (Xue et al. 2011) and may therefore be
involved in APP self-association. The E2 domain has a heparin-binding site (Multhaup 1994; Claris et al. 1997) as well as a number of putative metal-binding sites that may hold the E2 domain in a rigid conformation (Dahms et al. 2012). The metal-binding site in the E2 domain has been suggested to possess a ferrooxidase activity, which may function in cellular iron export through an interaction with ferroportin (Duce et al. 2010). A role in metal homeostasis is supported by the finding that levels of holo-APP can be regulated by iron (Rogers et al. 2002), although more work is needed in this area to support this idea.

**Chondroitin sulphate attachment domain**

An unusual spliced variant of APP (L-APP) is formed by splicing out exon 15. This creates a consensus sequence for the attachment of chondroitin sulphate (Pangalos et al. 1995). The proteoglycan form of APP (called 'appican'), which is formed as a consequence of this splicing event, has been found mostly in glia rather than in neurons. Appican contains a chondroitin sulphate E in the repeating disaccharide region and a 4-O-sulphated galactose in the linkage region (Tsuchida et al. 2001). Although the function of appican is unclear, it may be involved in adhesion events (Wu et al. 1997), as chondroitin sulphates are known to inhibit cell attachment and neurite outgrowth (Cui et al. 2013). In addition, appican has been found to bind to certain heparin-binding growth factors such as midkine and pleiotrophin, suggesting that the protein may play some role in the regulation of cell growth (Umehara et al. 2004).

**Aβ, transmembrane domain and intracellular domain**

The Aβ region on the C-terminal side of the E2 domain lies partly within the ectodomain and partly within the transmembrane domain. A GxxxG sequence motif within the transmembrane domain has been implicated in homodimerisation (Munter et al. 2007) and in cholesterol binding (Barrett et al. 2012; Fig. 2).

From a functional standpoint, the C-terminal cytoplasmic domain of APP is arguably the most interesting region. The structure and possible interactions of this region have been reviewed in detail elsewhere (Kerr and Small 2005; Schettini et al. 2010). The intracellular domain of APP is highly conserved among APP family members and contains a YENPTY sorting motif located between residues 757 and 762 of the APP770 isoform. This motif is involved in the facilitation of clathrin-mediated endocytosis and is present in many tyrosine receptor kinases, non-receptor tyrosine kinases, low-density lipoprotein-receptor related family proteins and integrins (Bonifacino and Traub 2003; Lemmon and Schlessinger 2010). Consistent with this role, many studies have demonstrated that the YENPTY motif in APP is involved in the regulation of its trafficking and endocytosis (Lai et al. 1995; Perez et al. 1999; Ring et al. 2007).

**Putative functions of APP**

Despite the large number of published studies on APP, there is still no clear consensus on the protein’s function. This section aims to summarise the major ideas relating to the function of APP. Coverage of more specific aspects of APP function can be found in other recent reviews (Aydin et al. 2012; Chasseigneaux and Allinquant 2012; Muller and Zheng 2012).

**Trophic actions of APP**

APP has been reported to influence cell proliferation, differentiation, neurite outgrowth, cell adhesion and synaptogenesis. A number of studies suggest that the extracellular domain can stimulate cellular growth. In vitro, sAPPα has been reported to alter the growth of fibroblasts, keratinocytes, B109 cells, FRTL-5 cells, PC12 cells and neurons (Saitoh et al. 1989; Araki et al. 1991; Milward et al. 1992; Jin et al. 1994; Ninomiya et al. 1994; Pietrzik et al. 1998; Hoffmann et al. 2000; Young-Pearse et al. 2008). Additionally, there are some reports that infusion of sAPPβ after traumatic brain injury can improve neuronal survival and recovery (Thornton et al. 2006). Genetic knock-in of sAPPα into APP/APLP2 double KO mice (APPsα-DM mice) rescues the lethal phenotype of the double KO (Weyer et al. 2011), supporting a role for sAPPα in growth. Similarly, knock-in of the extracellular domain fragment of APLP1 from C. elegans rescues the lethal phenotype of the APL-1 KO (Hornsten et al. 2007). Collectively, these studies provide good evidence that APP has a trophic function, and that the extracellular region of APP is involved in this function.

**Effects on neural stem cell proliferation and differentiation**

As APP is co-ordinately expressed in neuroblasts and neurons at the time of cell proliferation and differentiation (Fukuchi et al. 1992; Maslia et al. 1992; Salbaum and Ruddle 1994; Claris et al. 1995; Reinhard et al. 2005), this has led to the idea that APP may play a role in the regulation of stem-cell proliferation or differentiation. Indeed, APP is processed in a manner that is very similar to the protein Notch, which regulates neural stem cell differentiation (Ables et al. 2011). Therefore, it is possible that APP may have a similar or related developmental function to that of Notch (Kimberley et al. 2001).

There is strong evidence that APP is able to stimulate the proliferation of neural stem or progenitor cells (NSPCs). For example, sAPPα and sAPPβ can promote the proliferation of NSPCs (Hayashi et al. 1994; Ohsawa et al. 1999; Demars et al. 2011; Baratchi et al. 2012). Hayashi et al. (1994) examined the effect of secreted APP770 on NSPC proliferation and found secreted APP770 had a stronger effect on NSPC proliferation than secreted APP695. A more recent study reported that inhibition of α-secretase reduced
NSPC proliferation and that sAPPα was able to rescue this effect (Demars et al. 2011). In another study, sAPPα infused into the ventricles of mice was found to bind to epidermal growth factor receptor (EGFR) expressing stem cells in the subventricular zone (Caille et al. 2004). Both the secretion of EGF and the proliferation of the EGFR-expressing cells were increased by sAPPα infusion (Caille et al. 2004).

To examine the specific contribution of APP to stem cell proliferation, our group examined the ability of NSPCs derived from APP transgenic mice to proliferate. We found that the expression of APP positively correlated with the proliferation of NSPCs (Hu et al. 2013). However, surprisingly, the APP-induced increase in NSPC proliferation was not due to the secretion of sAPPα, but rather to the secretion of cystatin C (Hu et al. 2013). Therefore, APP could potentially influence NSPC proliferation through two different mechanisms, i.e. either via the production of sAPPα or via cystatin C release.

Studies on APP transgenic mice also suggest the possible involvement of APP in NSPC proliferation. Some studies have reported increased NSPC proliferation in APP mice, but have also suggested the effect was due to Aβ (Verret et al. 2007; Kolecik et al. 2008; Sothibundhu et al. 2009). J20 mice, which overexpress human APP with the Swedish and Indiana familial AD mutations, have a 2-fold increase in the number of proliferating stem cells in the dentate gyrus and subventricular zone at an age of 3 months (Jin et al. 2004; Lopez-Toledano and Shelanski 2007). In contrast, a number of studies have reported decreased NSPC proliferation in APP mice (Haughey et al. 2002; Dong et al. 2004; Donovan et al. 2006; Naumann et al. 2010) or no effect of APP on NSPC proliferation in vivo (Yetman and Jankowsky 2013). As Aβ starts to accumulate in APP mice, the proliferation of neural stem cells decreases (Lopez-Toledano and Shelanski 2007), suggesting that the build-up of Aβ may reduce stem cell proliferation.

APP may also play a role in regulating the differentiation of NSPCs. A study using human embryonic stem cells found that APP overexpression or addition of sAPPα enhanced neuronal differentiation (Freude et al. 2011). We also found that APP-overexpressing NSPCs derived from Tg2576 mice possessed a greater potential to differentiate into neurons, whereas cells derived from APP KO mice exhibited decreased neuronal differentiation (Hu et al. 2013). Another recent study has suggested that sAPPβ/β may cause an increase in glial cell differentiation (Baratchi et al. 2012). APP expression is probably not mandatory for the initiation of neuronal differentiation, as embryonic stem cells derived from APP triple KO mice still form neuronal precursors (Bergmans et al. 2010). However, the differentiation of neuronal precursors appears to be delayed in vivo when APP/APLP1 and APLP2 expression is reduced (Shariati et al. 2013).

Effects on neurite outgrowth, synaptogenesis and synaptic plasticity

APP can promote neurite outgrowth in cell culture (Small et al. 1994; Allinquant et al. 1995). Furthermore, APP expression is upregulated rapidly in axons in response to axonal injury, possibly as part of a repair mechanism (Gentleman et al. 1993). One possible mechanism by which APP promotes neurite outgrowth is by regulating cell-substrate adhesion. APP is reported to bind to laminin, collagen type I and heparan sulphate (Kibbey et al. 1993; Beher et al. 1996; Clarris et al. 1997), all of which can influence neurite outgrowth. APP may also promote cell-cell adhesion (Soba et al. 2005). For example, in the presence of heparin, APP can form trans-dimers that could form cell-to-cell contacts (Gralle et al. 2006; Dahms et al. 2010). This trans-dimerisation mode of action has also been proposed as a mechanism for the stabilisation of synapses by APP (Wang et al. 2009). APP may also modulate the activity of other proteins involved in cell adhesion. APP reportedly interacts with several cell-adhesion molecules including integrins, fasciclin II, contactin 4, neuroglia cell adhesion molecule, and transient axonal glycoprotein-1 (Yamazaki et al. 1997; Ashley et al. 2005; Ma et al. 2008; Osterfield et al. 2008). These studies suggest a number of mechanisms by which APP may influence adhesion, although the precise mechanisms still remain obscure.

APP may also be involved in the regulation of synaptogenesis. During development, APP is expressed in both pre- and postsynaptic sites and its level is dramatically increased during the critical period of synaptogenesis (Loffler and Huber 1992; Clarris et al. 1995; Wang et al. 2009). Clarris et al. (1995) found that APP expression was increased in mitral cells of the olfactory bulb at precisely the stage when neurites from olfactory receptor neurons were coming in contact with the mitral cell dendrites. In neurons, a pool of APP is also preferentially found in the post-synapse, suggesting a synaptic role for this protein (Shigematsu et al. 1992).

APP KO mice display a number of neurological deficiencies that may be explained by an effect on synaptogenesis, such as a deficit in grip strength and locomotor activity (Zheng et al. 1995; Ring et al. 2007). APP-KO mice also have a number of deficits that are associated with altered synaptic function, such as hypersensitivity to kainate-induced seizures, alterations in dendritic spine density, and reduced performance in tests of spatial memory (Steinbach et al. 1998; Dawson et al. 1999). APP/APLP2 double KO mice have impaired neuromuscular junction formation, as demonstrated by a reduced number of synaptic vesicles, excessive terminal sprouting, incorrect apposition of pre- and postsynaptic proteins and impaired synaptic transmission (Wang et al. 2005). These synaptic deficits may be responsible for the lethality of the APP/APLP2 double KO (Wang et al. 2005).
A role for APP in regulating synaptic plasticity, learning and memory has also been proposed. APP may alter expression of the GluR2 subunit of the \(\alpha\)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, which plays an important role in regulating synaptic calcium permeability (Lee et al. 2010). APP may also affect synaptic calcium by altering cell-surface expression of the NMDA receptor (Cousins et al. 2009; Hoe et al. 2009). As sAPP\(\alpha\) is secreted during long-term potentiation (LTP) (Fazeli et al. 1994), it may play a role in the regulation of LTP. However, whether cognitive deficits in APP mice (Chapman et al. 1999) are due to APP-induced disruption of LTP (Weyer et al. 2011) or whether they are due to effects of A\(\beta\), as seems likely (Janus et al. 2000; Morgan et al. 2000), remains to be established. Indeed, some studies suggest that APP can directly increase LTP (Ishida et al. 1997; Seabrook et al. 1999; Taylor et al. 2008).

**Function of APP in blood coagulation**

The predominant forms of APP in blood contain the KPI domain (Bush et al. 1990; Gardella et al. 1990; Van Nostrand et al. 1991a). These isoforms have been suggested to have a role in the regulation of blood coagulation. In platelets, APP, sAPP and A\(\beta\) accumulate in \(\alpha\)-granules, which are vesicles that store a variety of clotting factors (Van Nostrand et al. 1991b; Blair and Flaumenhaft 2009). Upon platelet stimulation, APP, sAPP and A\(\beta\) are released, along with a number of another components of the coagulation cascade (Bush et al. 1990; Gardella et al. 1990; Smith et al. 1990; Van Nostrand et al. 1990; Smith 1997). The KPI domain of APP is a potent inhibitor of the coagulation factors Xla, IXa and Xa (Smith et al. 1990; Schmaier et al. 1993; Scandura et al. 1997). Factor Xla, for example, is strongly inhibited (\(K_i = 400\) pM) (Smith et al. 1990; Scandura et al. 1997). Notwithstanding the role of the KPI domain, other regions of APP may also participate. For example, inhibition of factor Xla by APP is enhanced in presence of heparin, suggesting an involvement of the heparin-binding regions of APP (Smith et al. 1990). The E1 N-terminal heparin-binding domain of APP is also reported to inhibit the activation of factor XII and to inhibit platelet activation, independently of the KPI domain (Niwano et al. 1995; Henry et al. 1998).

KPI-containing forms of APP can inhibit blood coagulation in vitro, consistent with a role of APP as an inhibitor of coagulation (Schmaier et al. 1993; Annich et al. 1999). Genetic overexpression of APP in mice decreases cerebral thrombosis and also increases the severity of haemorrhage in animal models, whereas KO of APP has the opposite effect (Xu et al. 2005, 2007). The anti-coagulant function of APP is also conserved among APP family members (Xu et al. 2009). Therefore in the circulatory system, other APP family members may also have functions in the clotting cascade.

**What is the mechanism of APP signalling?**

Despite the many reports of effects of APP on cell proliferation, neurite outgrowth and synaptogenesis, the mechanisms that underlie these effects have not been fully elucidated. The original description of the APP gene noted that the structure of APP resembles a cell-surface receptor (Kang et al. 1987), however a receptor function for APP has not been unequivocally established. A major missing piece of information is the identity of a physiological ligand that activates the APP ‘receptor’. F-spondin has been suggested to be a potential APP ligand (Ho and Sudhof 2004). However, the strongest support for the idea that APP functions as a receptor comes from studies that suggest APP can activate intracellular signal transduction mechanisms.

The C-terminal domain (residues 732-751) has been suggested to be a binding site for G-proteins (Nishimoto et al. 1993). The binding of an extracellular antibody to the N-terminal domain of APP may result in signal transduction by activating the guanosine 5’-triphosphate-binding protein G\(\alpha_0\) (Okamoto et al. 1995; Murayama et al. 1996). The significance of G-protein coupled APP signalling has yet to be fully elucidated, but studies of the insect APP homologue APPL suggest that an APP-G-protein interaction could be involved in the control of neuronal migration (Ramaker et al. 2013).

Other mechanisms of signal transduction have also been proposed. APP has been suggested to activate gene transcription in a similar manner to Notch, which signals through the \(\gamma\)-secretase-mediated release of the Notch intracellular domain. This domain translocates to the nucleus and activates gene transcription. The AICD fragment of APP has also been reported to translocate to the nuclei (Cupers et al. 2001; Gao and Pimplikar 2001). Normally AICD is prone to degradation (Kimberly et al. 2001). However, AICD can be bound by Fe65, which binds to the YENPTY motif through its phosphotyrosine-binding domain (Fiore et al. 1995). Fe65 binding may help to stabilise AICD (Kimberly et al. 2001). After translocating to the nucleus, the Fe65-bound AICD has been reported to form a transcriptionally active complex in combination with Tat-interactive protein 60 (Tip60), which is a histone acetyltransferase (Cao and Sudhof 2001; Gao and Pimplikar 2001). A number of target genes have been reported for AICD. These genes include KAI1 (Baek et al. 2002), APP, BACE, Tip60 (von Rotz et al. 2004), glycogen synthase kinase-3\(\beta\) (Kim et al. 2003), EGFR (Zhang et al. 2007), p53 (Checler et al. 2007), nepriysin (Belyaev et al. 2009) and low-density lipoprotein-receptor related family proteins (Liu et al. 2007).

Despite the evidence that the AICD may be involved in the regulation of gene transcription, some studies suggest that the role of AICD may not be quite so straightforward. For example, \(\gamma\)-secretase-induced AICD release is not necessary
for Tip60 activation (Hass and Yankner 2005). Fe65 has also been reported to signal gene transcription independently of APP (Yang et al. 2006). Additionally, many of the downstream gene targets of the proposed AICD complex have been questioned (Chen and Selkoe 2007; Repetto et al. 2007; Waldron et al. 2008; Aydin et al. 2011) and the mechanism is still unclear (Chen and Selkoe 2007; Waldron et al. 2008).

APP may also exert its physiological effects via the secreted fragments sAPPα or sAPPβ. At present, it is not clear whether secreted APP can activate a specific signal transduction pathway via, for example, a growth factor receptor. Binding studies suggest that there is a high-affinity receptor for secreted APP, which interacts with the E1 domain (Reinhard et al. 2013). However, this receptor has not yet been identified. Some putative APP receptors include β1-integrin, lipoprotein receptor related protein-1, class A scavenger receptor, death receptor 6, p75 neurotrophin receptor and APP itself (Kounnas et al. 1995; Santiago-Garcia et al. 2001; Young-Pearse et al. 2008; Gralle et al. 2009; Nikolaev et al. 2009). However, APP may interact with many other extracellular proteins as well (Bai et al. 2008).

To complicate matters, APP’s trophic effects may be mediated via other growth factors. For example, sAPP is able to potentiate the action of nerve growth factor (NGF) (Milward et al. 1992; Wallace et al. 1997; Akar and Wallace 1998). APP can also increase the secretion and expression of cystatin C, which positively modulates the growth of NSPCs. (Hu et al. 2013). APP has been suggested to regulate NGF/tyrosine receptor kinase A signalling, through an intracellular interaction involving the C-terminal YENPTY phosphorylation site (Matrone et al. 2011). Along similar lines, NGF, EGF, and fibroblast growth factor-2 have all been reported to increase the expression of APP (Ohyagi and Tabira 1993; Villa et al. 2001) and NGF, EGF and insulin have been reported to increase the secretion of sAPP (Slack et al. 1995; Solano et al. 2000; Ruiz-Leon and Pascual 2001; Caillé et al. 2004). The interplay between these growth factor pathways and APP not only suggest that APP is linked to cellular growth, but also presents a challenge for establishing the direct signalling mechanisms undertaken by APP.

It has also been suggested that the production of Aβ from APP may represent a normal physiological function. However, this suggestion has been controversial. Aβ neither possesses a defined primary structure, nor is it produced as a major pathway of APP processing. Nevertheless, a number of functions for Aβ have been proposed. For example, Aβ has been suggested to be involved in cholesterol transport (Yao and Papadopoulos 2002) and Aβ peptides can increase cell adhesion and neurite outgrowth (Koo et al. 1993). Kamenetz et al. (2003) found that synaptic activity regulated Aβ production and that Aβ, in turn, selectively suppressed excitatory neurotransmission, suggesting that synaptic activity may be regulated by a negative feedback loop involving Aβ secretion. In contrast, a more recent study by Abramov et al. (2009) has suggested that Aβ is a positive endogenous regulator of release probability at hippocampal synapses. The identification of Aβ’s normal physiological function (if it has one) is extremely important. As many therapeutic strategies for the treatment of AD aim to prevent Aβ production or increase Aβ clearance from the brain, it is important to ensure that these strategies do not disrupt a normal physiological function.

Summary and conclusions

There is strong evidence that APP plays an important role in cell growth and proliferation. There is also evidence that APP may act as a trophic factor to influence events such as neurite outgrowth and synaptogenesis. As APP is expressed at early stages of nervous system development, APP clearly plays a key role in the growth and maturation of many cells. However, the expression of APP in the mature brain and the up-regulation of APP following traumatic brain injury argue for an important tissue-repair function as well.

Although the role of APP as a growth-regulatory molecule can now be stated with some confidence, the precise mechanism by which APP regulates cell growth is still unclear. The extracellular domain of APP may interact with a cell-surface receptor or a component of the extracellular matrix. The intracellular domain is also undoubtedly important and may interact with a number of cytoplasmic adaptor molecules to facilitate signal transduction or control APP trafficking. However, further research is needed to understand APP’s mechanism of action. In particular, future research needs to focus on mechanisms of APP action in which the function of APP is most clearly established. By understanding the mechanism of APP action in well-defined roles (e.g. NSPC proliferation), it may be possible to generalise the findings to understand the mechanisms of APP in relation to other less well-defined roles.

Acknowledgements and conflict of interest disclosure

This work was funded through grants to DHS from the National Health and Medical Research Council of Australia. All experiments were conducted in compliance with the ARRIVE guidelines. The authors have no conflict of interest to declare.

References

Ables J. L., Breunig J. J., Eisch A. J. and Rakic P. (2011) Not(ch) just development: notch signalling in the adult brain. Nat. Rev. Neurosci. 12, 269–283.
Abramov E., Dolev I., Fogel H., Ciccoottost G. D., Ruff E. and Slutsky I. (2009) Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat. Neurosci. 12, 1567–1576.
Akar C. A. and Wallace W. C. (1998) Amyloid precursor protein modulates the interaction of nerve growth factor with p75 receptor.
and potentiates its activation of trkA phosphorylation. *Brain Res. Mol. Brain Res.* 56, 125–132.

Allinquant B., Hantraye P., Mailleux P., Moya K., Bouillot C. and Prochiantz A. (1995) Downregulation of amyloid precursor protein inhibitors neurite outgrowth in vitro. *J. Cell Biol.* 128, 919–927.

Annich G., White T., Dann M., Zhao Y., Mahdi F., Meinhardt J., Rebello S., Lucchesi B., Bartlett R. H. and Schmaier A. H. (1999) Recombinant Kunitz protease inhibitory domain of the amyloid-beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. *Thromb. Haemost.* 82, 1474–1481.

Araki W., Kitaguchi N., Tokushima Y., Ishii K., Aratake H., Shimohama S., Nakamura S. and Kimura J. (1991) Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. *Biochem. Biophys. Res. Commun.* 181, 265–271.

Ashley J., Packard M., Ataman B. and Budnik V. (2005) Fasciclin II signals new synapse formation through amyloid precursor protein and the scaffolding protein dX11/Mint. *J. Neurosci.* 25, 5943–5955.

Aydin D., Filippow M. A., Tschape J. A., Gretz N., Prinz M., Eils R., Brors B. and Muller U. C. (2011) Comparative transcriptome profiling of amyloid precursor protein family members in the adult cortex. *BMC Genomics* 12, 160.

Aydin D., Weyer S. W. and Muller U. C. (2012) Functions of the APP gene family in the nervous system: insights from mouse models. *Exp. Brain Res.* 217, 423–434.

Baek S. H., Ohgi K. A., Rose D. W., Koo E. H., Glass C. K. and Rosenfeld M. G. (2002) Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. *Cell* 110, 55–67.

Bai Y., Markham K., Chen F. et al. (2008) The in vivo brain interactome of the amyloid precursor protein. *Mol. Cell. Proteomics* 7, 15–34.

Baratchy S., Evans J., Tate W. P., Abraham W. C. and Connor B. (2012) Secreted amyloid precursor proteins promote proliferation and glial differentiation of adult hippocampal neural progenitor cells. *Hippocampus* 22, 1517–1527.

Barrett P. J., Song Y., Van Horn W. D., Hustede E. J., Schafer J. M., Hadziselimovic A., Beel A. J. and Sanders C. R. (2012) The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. *Science* 336, 1168–1171.

Beher D., Hesse L., Masters C. L. and Multhaup G. (1996) Regulation of the binding sites on APP and collagen type I. *J. Biol. Chem.* 271, 1671–1620.

Belyaev N. D., Nalivaeva N. N., Makova N. Z. and Turner A. J. (2009) Beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. *Thromb. Haemost.* 82, 1474–1481.

Bonifacino J. S. and Traub L. M. (2003) Signals for sorting of transmembrane proteins to endosomes and lysosomes. *Annu. Rev. Biochem.* 72, 395–447.

Bozulak E. C. and Weinmaster G. (2009) Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. *Mol. Cell. Biol.* 29, 5679–5695.

Bush A. I., Martins R. N., Rumble B. et al. (1990) The amyloid precursor protein of Alzheimer’s disease is released by human platelets. *J. Biol. Chem.* 265, 15977–15983.

Bush A. I., Multhaup G., Moir R. D., Williamson T. G., Small D. H., Rumble B., Pollwein P., Beyreuther K. and Masters C. L. (1993) A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer’s disease. *J. Biol. Chem.* 268, 16109–16112.

Buxbaum J. D., Liu K. N., Luo Y., Slack J. L., Stocking K. L., Peschon J. J., Johnson R. S., Castner B. J., Cerretti D. P. and Black R. A. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. *J. Biol. Chem.* 273, 27765–27767.

Caille I., Allinquant B., Dupont E., Bouillot C., Langer A., Muller U. and Prochiantz A. (2004) Soluble form of amyloid precursor protein regulates proliferation of progenitors in the adult subventricular zone. *Development* 131, 2173–2181.

Cao X. and Sudhof T. C. (2001) A transcriptionally [correction of transcrip
tively] active complex of APP with F665 and histone acetyltransferase Tip60. *Science* 293, 115–120.

Chapman P. F., White G. L., Jones M. W. et al. (1995) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. *Nat. Neurosci.* 2, 271–276.

Chasseigneaux S. and Allinquant B. (2012) Functions of Abeta, sAPPalpha and sAPPbeta: similarities and differences. *J. Neurochem.* 120(Suppl 1), 99–108.

Checcher F., Sunyach C., Pardossi-Piquard R., Sevalle J., Vincent B., Kawarai T., Girardot N., St George-Hyslop P. and da Costa A. C. (2007) The gamma/epsilon-secretase-derived APP intracellular domain fragments regulate p53. *Curr. Alzheimer Res.* 4, 423–426.

Chen A. C. and Selkoe D. J. (2007) Response to: Pardossi-Piquard et al., ‘Presenilin-dependent transcriptional control of the abeta-degrading enzyme neprilysin by intracellular domains of betaAPP and APLP’. *Neuron* 46, 541–554. *Neuron* 53, 479–483.

Clark M. J., Gagnon J., Williams A. F. and Barclay A. N. (1985) MRC OX-2 antigen: a lymphoid/neuronal membrane glycoprotein with a structure like a single immunoglobulin light chain. *EMBO J.* 4, 113–118.

Clariss H. J., Key B., Beyreuther K., Masters C. L. and Small D. H. (1995) Expression of the amyloid precursor protein of Alzheimer’s disease in the developing rat olfactory system. *Brain Res. Dev. Brain Res.* 88, 87–95.

Clariss H. J., Cappai R., Heffernan D., Beyreuther K., Masters C. L. and Small D. H. (1997) Identification of heparin-binding domains in the amyloid precursor protein of Alzheimer’s disease by deletion mutagenesis and peptide mapping. *J. Neurochem.* 68, 1164–1172.

Cousins S. L., Hoey S. E., Anne Stephenson F. and Perkinton M. S. (2014) Identi
cation of amyloid precursor protein family members in the adult cyclin-dependent kinase 9. *EMBO Rep.* 15, 94–100.

Dahms S. O., Hoege S., Roesser D., Schlott B., Guhrs K. H. and Than M. E. (2010) Structure and biochemical analysis of the...
heparin-induced E1 dimer of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 107, 5381–5386.

Dahms S. O., Konig I., Roeser D., Guhrs K. H., Mayer M. C., Kaden D., Multhaup G. and Than M. E. (2012) Metal binding dictates conformation and function of the amyloid precursor protein (APP) E2 domain. J. Mol. Biol. 416, 438–452.

Dawson G. R., Seabrook G. R., Zheng H. et al. (1999) Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience 90, 1–13.

De Strooper B., Saiget P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K. and Van Leuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387–390.

De Strooper B., Annaert W., Cupers P. et al. (1999) A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398, 518–522.

Demars M. P., Bartholomew A., Strakova Z. and Lazarov O. (2011) Soluble amyloid precursor protein: a novel proliferation factor of adult progenitor cells of ectodermal and mesodermal origin. Stem Cell Res. Ther. 2, 36.

Dong H., Goico B., Martin M., Csernansky A. C., Berchume A. and Csernansky J. G. (2004) Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw mice. Cell Res. Ther. 6, 70–83.

Duce J. A., Tsatsanis A., Cater M. A. et al. (2010) Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 142, 857–867.

Fazeli M. S., Breen K., Errington M. L. and Bliss T. V. (1994) Increase of soluble amyloid precursor protein family members. J. Neurochem. 60, 601–609.

Donovan M. H., Yazdani U., Norris R. D., Games D., German D. C. and Eisch A. J. (2006) Decreased adult hippocampal neurogenesis in the PDAPP mouse model of Alzheimer’s disease. J. Comp. Neurol. 495, 70–83.

Duce J. A., Tsatsanis A., Cater M. A. et al. (2010) Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer’s disease. Cell 142, 857–867.

Fazeli M. S., Breen K., Errington M. L. and Bliss T. V. (1994) Increase in extracellular NCAM and amyloid precursor protein following induction of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci. Lett. 169, 77–80.

Fiore F., Zambrano N., Minopoli G., Donini V., Duilio A. and Russo T. (1995) The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Src bind the intracellular domain of the Alzheimer’s amyloid precursor protein. J. Biol. Chem. 270, 30853–30856.

Fleck D., van Bebber F., Colombo A. et al. (2013) Dual cleavage of neuregulin I type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling. J. Neurosci. 33, 7856–7869.

Francis R., McGrath G., Zhang J. et al. (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3, 85–97.

Freude K. K., Penjwini M., Davis J. L., LaFerla F. M. and Blument-Jones M. (2011) Soluble amyloid precursor protein induces rapid neural differentiation of human embryonic stem cells. J. Biol. Chem. 286, 24264–24274.

Fukuchi K., Deeb S. S., Kamino K., Ogburn C. E., Snow A. D., Sekiguchi R. T., Wight T. N., Piussan H. and Martin G. M. (1992) Increased expression of beta-amyloid precursor protein and microtubule-associated protein tau during the differentiation of murine embryonal carcinoma cells. J. Neurochem. 58, 1863–1873.

Gao Y. and Pimpiklar S. W. (2001) The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc. Natl Acad. Sci. USA 98, 14979–14984.

Gardella J. E., Ghiso J., Gorgone G. A., Marratta D., Kaplan A. P., Frangione B. and Gorevic P. D. (1990) Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA. Biochem. Biophys. Res. Commun. 173, 1292–1298.

Gentleman S. M., Nash M. J., Sweeting C. J., Graham D. L. and Roberts G. W. (1993) Beta-amyloid precursor protein (beta APP) as a marker for axonal injury after head injury. Neurosci. Lett. 160, 139–144.

Glenner G. G. and Wong C. W. (1984) Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131–1135.

Graller M., Oliveira C. L., Guerreiro L. H. et al. (2006) Solution conformation and heparin-induced dimerization of the full-length extracellular domain of the human amyloid precursor protein. J. Mol. Biol. 357, 493–508.

Gralle M., Botelho M. G. and Wouters F. S. (2009) Neuroprotective secreted amyloid precursor protein acts by disrupting amyloid precursor protein dimers. J. Biol. Chem. 284, 15016–15025.

Haapasaalo A. and Kovacs D. M. (2011) The many substrates of presenilin/γ-secretase. J. Alzheimers Dis. 25, 3–28.

Haass C., Koo E. H., Mellon A., Hung A. Y. and Selkoe D. J. (1992) Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature 357, 500–503.

Haass C., Kaether C., Thirakaran G. and Sisodia S. (2012) Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270.

Haass M. R. and Yankner B. A. (2005) A γ-secretase-independent mechanism of signal transduction by the amyloid precursor protein. J. Biol. Chem. 280, 36985–36904.

Haughey N. J., Nath A., Chan S. L., Borchard A. C., Rao M. S. and Mattson M. P. (2002) Disruption of neurongenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer’s disease. J. Neurochem. 83, 1509–1524.

Hayashi Y., Kashiwagi K., Ohta J., Nakajima M., Kawashima T. and Yoshikawa K. (1994) Alzheimer amyloid protein precursor enhances proliferation of neural stem cells from fetal rat brain. Biochem. Biophys. Res. Commun. 205, 936–943.

Heber S., Herms J., Gajic V. et al. (2000) Mice with combined gene knockouts reveal essential and partially redundant functions of amyloid precursor protein family members. J. Neurosci. 20, 7951–7963.

Henry A., Li Q. X., Galatis D., Hesse L., Multhaup G., Beyreuther K., Masters C. L. and Cappai R. (1998) Inhibition of platelet activation by the Alzheimer’s disease amyloid precursor protein. Br. J. Haematol. 103, 402–415.

Ho A. and Sudhof T. C. (2004) Binding of F-spondin to amyloid-beta precursor protein: a candidate amyloid-beta precursor protein ligand that modulates amyloid-beta precursor protein cleavage. Proc. Natl Acad. Sci. USA 101, 2548–2553.

Hoe H. S., Fu Z., Makarova A. et al. (2009) The effects of amyloid precursor protein on postsynaptic composition and activity. J. Biol. Chem. 284, 8495–8506.

Hoffmann J., Twieselmarrn C., Kummer M. P., Romagnoli P. and Herzog V. (2000) A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation. Eur. J. Cell Biol. 79, 905–914.

Hornsten A., Lieberthal J., Fadia S. et al. (2007) APL-1, a Caenorhabditis elegans protein related to the human beta-amyloid precursor protein, is essential for viability. Proc. Natl Acad. Sci. USA 104, 1971–1976.

Hu Y., Hung A. C., Cui H., Dawkins E., Bolos M., Foa L., Young K. M. and Small D. H. (2013) Role of cystatin C in amyloid precursor protein-induced proliferation of neural stem/progenitor cells. J. Biol. Chem. 288, 18853–18862.

Hussain I., Powell D., Howlett D. R. et al. (1999) Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol. Cell. Neurosci. 14, 419–427.
Ishida A., Furukawa K., Keller J. N. and Mattson M. P. (1997) Secreted form of beta-amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices. *NeuroReport* 8, 2133–2137.

Izumi R., Yamada T., Yoshikai S., Sasaki H., Hattori M. and Sakaki Y. (1992) Positive and negative regulatory elements for the expression of the Alzheimer’s disease amyloid precursor-encoding gene in mouse. *Gene* 112, 189–195.

Janus C., Pearson J., McLaurin J. et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. *Nature* 408, 979–982.

Jin L. W., Ninomiya H., Roch J. M., Schubert D., Masthia E., Otero D. A. and Saitoh T. (1994) Peptides containing the RERMS sequence of amyloid beta/4 protein precursor bind cell surface and promote neurite extension. *J. Neurosci.* 14, 5461–5470.

Jin K., Galvan V., Xie L., Mao X. O., Gorostiza O. F., Bredesen D. E. and Greenberg D. A. (2004) Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw, Ind) mice. *Proc. Natl Acad. Sci. USA* 101, 13363–13367.

Kamenetz F., Tomita T., Hsieh H., Seabrook G., Borchelt D., Iwatsubo J., Jin K., Galvan V., Xie L., Mao X. O., Gorostiza O. F., Bredesen D. E. and Greenberg D. A. (2004) Enhanced neurogenesis in Alzheimer’s disease transgenic (PDGF-APPSw, Ind) mice. *Proc. Natl Acad. Sci. USA* 101, 13363–13367.

Klaver D. W., Wilce M. C., Cui H., Hung A. C., Gasperini R., Foa L. (2008) The effect of amyloidosis-beta and cation of ADAM10 as a substrate interacts with extracellular matrix to promote neurite outgrowth. *Proc. Natl Acad. Sci. USA* 90, 4748–4752.

Koo E. H., Park L. and Selkoe D. J. (1993) Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. *Proc. Natl Acad. Sci. USA* 90, 4748–4752.

Koo E. H., Sazouko S. L., Selkoe D. J. and Koo C. H. (1996) Trafficking of cell-surface amyloid beta-protein precursor. I. Secretion, endocytosis and recycling as detected by labeled monoclonal antibody. *J. Cell. Sci.* 109, 991–998.

Koumnas M. Z., Moir R. D., Rebeck G. W., Bush A. L., Argraves W. S., Tanzi R. E., Hyman B. T. and Strickland D. K. (1995) LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. *Cell* 82, 331–340.

Lai A., Sisodia S. S. and Trowbridge I. S. (1995) Characterization of sorting signals in the beta-amyloid precursor protein cytoplasmic domain. *J. Biol. Chem.* 270, 3565–3573.

Lammich S., Kojo E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C. and Frauenholz F. (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. *Proc. Natl Acad. Sci. USA* 96, 3922–3927.

Lee K. J., Moussa C. E., Lee Y., Sung Y., Howell B. W., Turner R. S., Pak D. T. and Hoe H. S. (2010) Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. *Neuroscience* 169, 344–356.

Levenson M. A. and Schlessinger J. (2010) Cell signaling by receptor tyrosine kinases. *Cell* 141, 1117–1134.

Lichtenhager S., Haass C. and Steiner H. (2011) Regulated intramembrane proteolysis—lessons from amyloid precursor protein processing. *J. Neurochem.* 117, 779–796.

Lin X., Koelsch G., Wu S., Downs D., Dashi A. and Tang J. (2000) Human asparatic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. *Proc. Natl Acad. Sci. USA* 97, 1456–1460.

Liu K., Doms R. W. and Lee V. M. (2002) Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. *Biochemistry* 41, 3128–3136.

Liu P. C., Liu X., Li Y. et al. (2006) Identification of ADAM10 as a major source of HER2 ectodomain shedding activity in HER2 overexpressing breast cancer cells. *Cancer Biol. Ther.* 5, 657–664.

Liu Q., Zerbinatti C. V., Zhang J., Hoe H. S., Wang B., Cole S. L., Herz J., Muglia L. and Bu G. (2007) Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LR1. *Neuron* 56, 66–78.

Liu X., Yu X., Zack D. J., Zha H. and Qian J. (2008) TGER: a database for tissue-specific gene expression and regulation. *BMC Bioinformatics* 9, 271.

Loffler J. and Haber G. (1992) Beta-amyloid precursor protein isoforms in various rat brain regions and during brain development. *J. Neurochem.* 59, 1316–1324.

Lopez-Toledano M. A. and Shelanski M. L. (2007) Increased neurogenesis in young transgenic mice overexpressing human APP(Sw, Ind). *J. Alzheimers Dis.* 12, 229–240.

Luo L., Tully T. and White K. (1992) Human amyloid precursor-encoding gene in HER2 overexpressing breast cancer cells. *Cancer Biol. Ther.* 5, 657–664.

Ma H. Q., Fatagawa T., Yang W. L. et al. (2008) A TAG1-APP signaling pathway through F65 negatively modulates neurogenesis. *Nat. Cell Biol.* 10, 283–294.

Magara F., Muller U., Li Z. W., Lipp H. P., Weissmann C., Stagljar M. and Wolfe D. P. (1999) Genetic background changes the pattern of forebrain commissure defects in transgenic mice underexpressing...
the beta-amyloid-precursor protein. Proc. Natl Acad. Sci. USA 96, 4656–4661.

Masliah E., Mallory M., Ge N. and Saitoh T. (1992) Amyloid precursor protein is localized in growing neurites of neonatal rat brain. Brain Res. 593, 323–328.

Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. and Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245–4249.

Matrone C., Barbagallo A. P., La Rosa L. R., Florenzano F., Ciotti M. T., Mercanti D., Chao M. V., Calissano P. and D’Adamo L. (2011) APP is phosphorylated by TrkA and regulates NGF/TrkA signaling. J. Neurosci. 31, 11756–11766.

Milward E. A., Papadopoulos R., Fuller S. J., Small D., Beyreuther K. and Masters C. L. (1992) The amyloid protein precursor of Alzheimer’s disease is a mediator of the effects of nerve growth factor on neurite outgrowth. Neuron 9, 129–137.

Morgan D., Diamond D. M., Gottschall P. E. et al. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 408, 982–985.

Muller U. C. and Zheng H. (2012) Physiological functions of APP family proteins. Cold Spring Harb. Perspect. Med. 2, a006288.

Muller-Hill B. and Beyreuther K. (1989) Molecular biology of Alzheimer’s disease. Annus. Rev. Biochem. 58, 287–307.

Multhaup G. (1994) Identification and regulation of the high affinity binding site of the Alzheimer’s disease amyloid protein precursor (APP) to glycosaminoglycans. Biochimie 76, 304–311.

Multhaup G., Schlicksupp A., Hesse L., Beher D., Ruppert T., Masters C. L. and Beyreuther K. (1996) The amyloid protein precursor of Alzheimer’s disease in the reduction of copper(II) to copper(I). Science 271, 1406–1409.

Munter L. M., Voigt P., Harmeier A., Kaden D., Gottschall K. E., Weise C., Pijikorn R., Schaefer M., Langosch D. and Multhaup G. (2007) GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. EMBO J. 26, 1702–1712.

Murayama Y., Takeda S., Yonezawa K., Giambarella U., Nishimoto I., Takamura C., Morimoto T., Chao M. V., Calissano P. and D’Adamo L. (1999) Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. Eur. J. Neurosci. 11, 1907–1913.

Ohyagi Y. and Tabira T. (1993) Effect of growth factors and cytokines on expression of amyloid beta protein precursor mRNAs in cultured neural cells. Brain Res. Mol. Brain Res. 18, 127–132.

Okamoto T., Takeda S., Murayama Y., Ogata E. and Nishimoto I. (1995) Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J. Biol. Chem. 270, 4205–4208.

Osterfeld M., Egelund R., Young L. M. and Flanagan J. G. (2008) Interaction of amyloid precursor protein with contactins and NgCAM in the retinotectal system. Development 135, 1189–1199.

Pangalos M. N., Shioi J. and Robakis N. K. (1995) Expression of the chondroitin sulfate proteoglycans of amyloid precursor (appican) and amyloid precursor-like protein 2. J. Neurochem. 65, 762–769.

Pangalos M. N., Shioi J., Efthimiopoulos S., Wu A. and Robakis N. K. (1996) Characterization of appican, the chondroitin sulfate proteoglycan form of the Alzheimer amyloid precursor protein. Neurodegeneration 5, 445–451.

Perez R. G., Soriano S., Hayes J. D., Ostaszewski B., Xia W., Selkoe D. J., Chen X., Stokin G. B. and Koo E. H. (1999) Mutagenesis identifies new signals for beta-amyloid precursor protein endocytosis, turnover, and the generation of secreted fragments, including Abet42. J. Biol. Chem. 274, 18851–18856.

Pietrzik C. U., Hoffmann J., Stober K., Chen C. Y., Bauer C., Otero D. A., Roch J. M. and Herzog V. (1998) From differentiation to proliferation: the secretory amyloid precursor protein as a local mediator of growth in thyroid epithelial cells. Proc. Natl Acad. Sci. USA 95, 1770–1775.

Quitschke W. W. and Goldgaber D. (1992) The amyloid beta-protein precursor promoter. A region essential for transcriptional activity contains a nuclear factor binding domain. J. Biol. Chem. 267, 17362–17368.

Ramaker J. M., Swanson T. L. and Copenhaver P. F. (2013) Amyloid precursor proteins interact with the heterotrimeric G protein Go in the control of neuronal migration. J. Neurosci. 33, 10165–10181.

Reinhard C., Hebert S. S. and De Strooper B. (2005) The amyloid-beta precursor protein: integrating structure with biological function. EMBO J. 24, 3996–4006.

Reinhard C., Borgers M., David G. and De Strooper B. (2013) Soluble amyloid-beta precursor protein binds its cell surface receptor in a cooperative fashion with glycan and syndecan proteoglycans. J. Cell Sci. 126, 4856–4861.

Repetto E., Yoon I. S., Zheng H. and Kang D. E. (2007) Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J. Biol. Chem. 282, 31504–31516.

Ring S., Weyer S. W., Kilian S. B. et al. (2007) The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 7817–7826.

Rogers J. T., Randall J. D., Cahill C. M. et al. (2002) An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J. Biol. Chem. 277, 45518–45528.

Rohan de Silva H. A., Jen A., Wickenden C., Jen L. S., Wilkinson S. L. and Patel A. J. (1997) Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes. Brain Res. Mol. Brain Res. 47, 147–156.

Rossjohn J., Cappai R., Feil S. C. et al. (1999) Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 6, 327–331.

von Rotz R. C., Kohli B. M., Bosset J., Meier M., Suzuki T., Nitsch R. M. and Konietzko U. (2004) The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci. 117, 4435–4448.
Ruiz-Leon Y. and Pascual A. (2001) Brain-derived neurotrophic factor stimulates beta-amyloid gene promoter activity by a Ras-dependent/AP-1-independent mechanism in SH-SYSY neuroblastoma cells. J. Neurochem. 79, 278–285.

Saito T., Sundsmo M., Roch J. M., Kimura N., Cole G., Schubert D., Ottersdorf T. and Schenk D. B. (1989) Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 58, 615–622.

Salbaum J. M. and Ruddle F. H. (1994) Embryonic expression pattern of amyloid protein precursor suggests a role in differentiation of specific subsets of neurons. J. Exp. Zool. 269, 116–127.

Salbaum J. M., Weidemann A., Lemaire H. G., Masters C. L. and Beyreuther K. (1988) The promoter of Alzheimer’s disease amyloid A4 precursor gene. EMBO J. 7, 2807–2813.

Santiago-Garcia J., Mas-Oliva J., Innerarity T. L. and Pitas R. E. (2001) Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J. Biol. Chem. 276, 30655–30661.

Scandura J. M., Zhang Y., Van Nostrand W. E. and Walsh P. N. (1997) Progress curve analysis of the kinetics with which blood coagulation factor Xa is inhibited by protease nexitin-2. Biochemistry 36, 412–420.

Schettini G., Govoni S., Racchi M. and Rodriguez G. (2010) Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role-relevance for Alzheimer pathology. J. Neurochem. 115, 1299–1308.

Schmaier A. H., Dahl L. D., Rozemuller A. J., Roos R. A., Wagner S. L., Chung R. and Van Nostrand W. E. (1993) Protease nexitin-2 amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor Xa. J. Clin. Invest. 92, 2540–2545.

Seabrook G. R., Smith D. W., Bowery B. J. et al. (1999) Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology 38, 349–359.

Selkoe D. J. (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol. Rev. 81, 741–766.

Selkoe D. J. (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidylinositol 3 kinase-dependent pathway. FASEB J. 14, 1015–1022.

Sotohribundu A., Li Q. X., Thangnipon W. and Coulson E. J. (2009) Abeta(1-42) stimulates adult SVZ neurogenesis through the p75 neurotrophin receptor. Neurobiol. Aging 30, 1975–1985.

Steinbach J. P., Muller U., Leist M., Li Z. W., Nicotera P. and Aguzzi A. (1998) Hypersensitivity to seizures in beta-amyloid precursor protein deficient mice. Cell Death Differ. 5, 858–866.

Struhl G. and Greenwald I. (1999) Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398, 522–525.

Tang K., Wang C., Shen C., Sheng S., Ravid R. and Jing N. (2003) Identification of a novel alternative splicing isoform of human amyloid precursor gene, APP639. Eur. J. Neurosci. 18, 102–108.

Tanzi R. E., McClatchey A. I., Lamperti E. D., Villa-Komaroff L., Gusella J. F. and Neve R. L. (1988) Protease inhibitor domain encoded by an amyloid protein precursor mRNA associated with Alzheimer’s disease. Nature 331, 528–530.

Taylor C. J., Ireland D. R., Ballagh I., Bourne K., Marechal N. M., Turner P. R., Bilkey D. K., Tate W. P. and Abraham W. C. (2008) Endogenous secreted amyloid protein precursor-alpha regulates hippocampal NMDA receptor function, long-term potentiation and spatial memory. Neurobiol. Dis. 31, 250–260.

Thornton E., Vink R., Blumbergs P. C. and Van Den Heuvel C. (2006) Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res. 1094, 38–46.

Tsuda K., Shioi J., Yamada S., Boghosian G., Wu A., Cai H., Sugahara K. and Robakis N. K. (2001) Appican, the proteoglycan form of the amyloid precursor protein, contains chondroitin sulfate E in the repeating disaccharide region and 4-O-sulfated galactose in the linkage region. J. Biol. Chem. 276, 37155–37160.

Umehara Y., Yamada S., Nishimura S., Shioi J., Robakis N. K. and Sugahara K. (2004) Chondroitin sulfate of appican, the proteoglycan form of amyloid precursor protein, produced by C6 glioma cells interacts with heparin-binding neuroregulatory factors. FEBS Lett. 557, 233–238.

Van Nostrand W. E., Schmaier A. H., Farrow J. S. and Cunningham D. D. (1990) Protease nexitin-II (amyloid beta-protein precursor): a platelet-alpha-granule protein. Science 245, 745–748.

Van Nostrand W. E., Schmaier A. H., Farrow J. S., Cines D. B. and Cunningham D. D. (1991a) Protease nexitin-2/amyloid beta-protein precursor in blood is a platelet-specific protein. Biochem. Biophys. Res. Commun. 175, 15–21.

Van Nostrand W. E., Schmaier A. H., Farrow J. S. and Cunningham D. D. (1991b) Platelet protease nexitin-2/amyloid beta-protein precursor. Possible pathologic and physiologic functions. J. Clin. Invest. 98, 140–144.

Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735–741.

Verret L., Jankowsky J. L., Xu G. M., Borchelt D. R. and Rampon C. (2007) Alzheimer’s-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J. Neurosci. 27, 6771–6780.

Villa A., Latasa M. J. and Pascual A. (2001) Nerve growth factor modulates the expression and secretion of beta-amyloid precursor protein through different mechanisms in PC12 cells. J. Neurochem. 79, 1077–1084.

Waldron E., Ishert S., Kern A., Jaeger S., Martin A. M., Hebert S. S., Behl C., Weggen S., De Strooper B. and Pietrzik C. U. (2008) Increased AICD generation does not result in increased nuclear translocation or activation of target gene transcription. Exp. Cell Res. 314, 2419–2433.
Wallace W. C., Akar C. A. and Lyons W. E. (1997) Amyloid precursor protein potentiates the neurotrophic activity of NGF. *Brain Res. Mol. Brain Res.* **52**, 201–212.

Wang H. and Reiser G. (2003) Thrombin signaling in the brain: the role of protease-activated receptors. *Biol. Chem.* **384**, 193–202.

Wang P., Yang G., Mosier D. R. *et al.* (2005) Defective neuronumcular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. *J. Neurosci.* **25**, 1219–1225.

Wang Z., Wang B., Yang L., Guo Q., Aithmitti N., Songyang Z. and Zheng H. (2009) Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. *J. Neurosci.* **29**, 10788–10801.

Wasco W., Bupp K., Magendantz M., Gusella J. F., Tanzi R. E. and Gusella J. F. (1992) Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. *Proc. Natl Acad. Sci. USA* **89**, 10758–10762.

Wasco W., Gurubhagavatula S., Paradis M. D., Romano D. M., Sisodia S. S., Hyman B. T., Neve R. L. and Tanzi R. E. (1993) Isolation and characterization of APLP2 encoding a homologue of the Alzheimer’s associated amyloid beta protein precursor. *Nat. Genet.* **5**, 95–100.

Weidemann A., Konig G., Bunke D., Fischer P., Salbaum J. M., Masters C. L. and Beyreuther K. (1989) Identification, biogenesis, and localization of precursors of Alzheimer’s disease A4 amyloid protein. *Cell* **57**, 115–126.

Weyer S. W., Klevanski M., Delekate A. *et al.* (2011) APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP. *EMBO J.* **30**, 2266–2280.

Wu Q. and Parry G. (2007) Hepsin and prostate cancer. *Front. Biosci.* **12**, 5052–5059.

Wu A., Pangalos M. N., Efthimiopoulos S., Shioti J. and Robakis N. K. (1997) Appican expression induces morphological changes in C6 glioma cells and promotes adhesion of neural cells to the extracellular matrix. *J. Neurosci.* **17**, 4987–4993.

Xu F., Davis J., Miao J., Previti M. L., Romanov G., Ziegler K. and Van Nostrand W. E. (2005) Protease nixin-2/amyloid beta-protein precursor limits cerebral thrombosis. *Proc. Natl Acad. Sci. USA* **102**, 18135–18140.

Xu F., Previti M. L. and Van Nostrand W. E. (2007) Increased severity of hemorrhage in transgenic mice expressing cerebral protease nixin-2/amyloid beta-protein precursor. *Stroke* **38**, 2598–2601.

Xu F., Previti M. L., Nieman M. T., Davis J., Schmaier A. H. and Van Nostrand W. E. (2009) AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. *J. Neurosci.* **29**, 5666–5670.

Xue Y., Lee S., Wang Y. and Ha Y. (2011) Crystal structure of the E2 domain of amyloid precursor protein-like protein 1 in complex with sucrose octasulfate. *J. Biol. Chem.* **286**, 29748–29757.

Yamazaki T., Koo E. H. and Selkoe D. J. (1996) Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. *J. Cell Sci.* **109**, 999–1008.

Yamazaki T., Koo E. H. and Selkoe D. J. (1997) Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. *J. Neurosci.* **17**, 1004–1010.

Yan R., Bienkowski M. J., Shuck M. E. *et al.* (1999) Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. *Nature* **402**, 533–537.

Yang Z., Cool B. H., Martin G. M. and Hu Q. (2006) A dominant role for FE65 (APBB1) in nuclear signaling. *J. Biol. Chem.* **281**, 4207–4214.

Yao Z. X., Yang Z., Cool B. H., Martin G. M. and Hu Q. (2006) A dominant role for FE65 (APBB1) in nuclear signaling. *J. Biol. Chem.* **281**, 4207–4214.

Young-Pearse T. L., Chen A. C., Chang R., Marquez C. and Selkoe D. J. (2005) Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. *Proc. Natl Acad. Sci. USA* **102**, 2598–2601.

Yu G., Nishimura M., Arawaka S., Wada Y., Seto Y. and Ohe Y. (2000) Nicastrin modulates Notch/glp-1 signal transduction and betaAPP processing. *Nature* **407**, 48–54.

Zhang Y. W., Wang R., Liu Q., Zhang H., Liao F. F. and Xu H. (2007) Increased severity of hemorrhage in transgenic mice expressing cerebral protease nixin-2/amyloid beta-protein precursor. *Stroke* **38**, 2598–2601.

Xu F., Previti M. L., Nieman M. T., Davis J., Schmaier A. H. and Van Nostrand W. E. (2009) AbetaPP/APLP2 family of Kunitz serine proteinase inhibitors regulate cerebral thrombosis. *J. Neurosci.* **29**, 5666–5670.

Xue Y., Lee S., Wang Y. and Ha Y. (2011) Crystal structure of the E2 domain of amyloid precursor protein-like protein 1 in complex with sucrose octasulfate. *J. Biol. Chem.* **286**, 29748–29757.

Yamazaki T., Koo E. H. and Selkoe D. J. (1996) Trafficking of cell-surface amyloid beta-protein precursor. II. Endocytosis, recycling and lysosomal targeting detected by immunolocalization. *J. Cell Sci.* **109**, 999–1008.

Yamazaki T., Koo E. H. and Selkoe D. J. (1997) Cell surface amyloid beta-protein precursor colocalizes with beta 1 integrins at substrate contact sites in neural cells. *J. Neurosci.* **17**, 1004–1010.

Yan R., Bienkowski M. J., Shuck M. E. *et al.* (1999) Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. *Nature* **402**, 533–537.

Yang Z., Cool B. H., Martin G. M. and Hu Q. (2006) A dominant role for FE65 (APBB1) in nuclear signaling. *J. Biol. Chem.* **281**, 4207–4214.

Yao Z. X. and Papadopoulos V. (2002) Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. *FASEB J.* **16**, 1677–1679.

Yetman M. J. and Jankowsky J. L. (2013) Wild-type neural progenitors divide and differentiate normally in an amyloid-rich environment. *J. Neurosci.* **33**, 17335–17341.

Yoshikai S., Sasaki H., Doh-ura K., Furuya H. and Sakaki Y. (1990) Genomic organization of the human amyloid beta-protein precursor gene. *Genet.* **87**, 257–263.

Young-Pearse T. L., Chen A. C., Chang R., Marquez C. and Selkoe D. J. (2008) Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. *Neural Dev.* **3**, 15.

Yu G., Nishimura M., Arawaka S. *et al.* (2000) Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. *Nature* **407**, 48–54.

Zhang Y. W., Wang R., Liu Q., Zhang H., Liao F. F. and Xu H. (2007) Presenilin/gamma-secretase-dependent processing of beta-amyloid precursor protein regulates EGF receptor expression. *Proc. Natl Acad. Sci. USA* **104**, 10613–10618.

Zheng H., Jiang M., Trumbauer M. E. *et al.* (1995) Beta-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. *Cell* **81**, 525–531.